Rybrevant (amivantamab-vmjw)

Adult Dosing .

Dosage forms:  INJ

Special Note

[formulation clarification]

Info: nonproprietary name = amivantamab-vmjw

[uses, dosing may vary]

Info: refer to institution protocols and pkg insert prior to prescribing for uses, premeds, and dosing incl. toxicity-related dose adjustments

non-small cell lung CA, locally advanced or metastatic

[EGFR exon 19 deletion mutation-positive dz or exon 21 (L858R) substitution mutation-positive dz, first-line tx, <80 kg]

Dose: 350 mg IV x1 on day 1 at wk 1, then 700 mg IV x1 on day 2 at wk 1, then 1050 mg IV qwk x4wk starting at wk 2, then 1050 mg IV q2wk starting at wk 7; Info: use w/ lazertinib

[EGFR exon 19 deletion mutation-positive dz or exon 21 (L858R) substitution mutation-positive dz, first-line tx, >80 kg]

Dose: 350 mg IV x1 on day 1 at wk 1, then 1050 mg IV x1 on day 2 at wk 1, then 1400 mg IV qwk x4wk starting at wk 2, then 1400 mg IV q2wk starting at wk 7; Info: use w/ lazertinib

[EGFR exon 19 deletion mutation-positive dz or exon 21 (L858R) substitution mutation-positive dz, progressive dz, <80 kg]

Dose: 350 mg IV x1 on day 1 at wk 1, then 1050 mg IV x1 on day 2 at wk 1, then 1400 mg IV qwk x3wk starting at wk 2, then 1750 mg IV q3wk starting at wk 7; Info: for pts w/ dz progression on or after EGFR TKI; part of multi-drug chemo regimen

[EGFR exon 19 deletion mutation-positive dz or exon 21 (L858R) substitution mutation-positive dz, progressive dz, >80 kg]

Dose: 350 mg IV x1 on day 1 at wk 1, then 1400 mg IV x1 on day 2 at wk 1, then 1750 mg IV qwk x3wk starting at wk 2, then 2100 mg IV q3wk starting at wk 7; Info: for pts w/ dz progression on or after EGFR TKI; part of multi-drug chemo regimen

[EGFR exon 20 insertion mutation-positive dz, first-line tx, <80 kg]

Dose: 350 mg IV x1 on day 1 at wk 1, then 1050 mg IV x1 on day 2 at wk 1, then 1400 mg IV qwk x3wk starting at wk 2, then 1750 mg IV q3wk starting at wk 7; Info: part of multi-drug chemo regimen

[EGFR exon 20 insertion mutation-positive dz, first-line tx, >80 kg]

Dose: 350 mg IV x1 on day 1 at wk 1, then 1400 mg IV x1 on day 2 at wk 1, then 1750 mg IV qwk x3wk starting at wk 2, then 2100 mg IV q3wk starting at wk 7; Info: part of multi-drug chemo regimen

[EGFR exon 20 insertion mutation-positive dz, progressive dz, <80 kg]

Dose: 350 mg IV x1 on day 1 at wk 1, then 700 mg IV x1 on day 2 at wk 1, then 1050 mg IV qwk x4wk starting at wk 2, then 1050 mg IV q2wk starting at wk 7; Info: for pts w/ dz progression on or after platinum-based chemo

[EGFR exon 20 insertion mutation-positive dz, progressive dz, >80 kg]

Dose: 350 mg IV x1 on day 1 at wk 1, then 1050 mg IV x1 on day 2 at wk 1, then 1400 mg IV qwk x4wk starting at wk 2, then 1400 mg IV q2wk starting at wk 7; Info: for pts w/ dz progression on or after platinum-based chemo

renal dosing

[see below]

eGFR >30: no adjustment; eGFR <30: not defined

HD/PD: not defined

hepatic dosing

[see below]

bilirubin <1.5x ULN: no adjustment; bilirubin >1.5x ULN: not defined

Peds Dosing .

Peds dosing is currently unavailable or not applicable for this drug.